Categories
Credit Cards

Merrill Lynch Stick to Their Buy Rating for CVS Health Corp

Merrill Lynch analyst Michael Cherny maintained a Buy rating on CVS Health Corp (NYSE:CVS) on Tuesday, setting a price target of $83, and that is more or less 9.11 % above the present share price of $76.07.

Cherny expects CVS Health Corp to publish earnings per share (EPS) of $0.93 for the first quarter of 2021.

The current opinion among 11 TipRanks analysts is for a modest Buy rating of shares in CVS Health, with an average price target of $84.

The analysts price targets range from a high of hundred one dolars to a low of sixty one dolars.

From its latest earnings report, released on 09/30/2020, the company reported a quarterly revenue of $67.06 billion and a net profit of $3.25 billion. The company’s market cap is actually $99.57 billion.

According to TipRanks.com, Merrill Lynch analyst Michael Cherny is currently ranked with four stars on a 0 5 stars ranking scale, with an average return of 11.5 % and a 60.53 % success rate.

CVS Health Corp. engages in the provision of health care services. It operates through the following segments: Pharmacy Services, Long or retail Term Care, Health Care Benefits, and Corporate. The Pharmacy Services segment provides pharmacy benefit management solutions. The Long or retail Term Care segment includes offering of prescribed drugs and assortment of general merchandise.

The Health Care Benefits segment offers traditional, voluntary and consumer-directed health insurance products as well as similar services, including medical, pharmacy, dental, behavioural health, medical control capabilities. The Corporate segment involves in offering management and administrative services. The company was founded by Stanley P. Goldstein and Ralph Hoagland in 1963 and it is headquartered in Woonsocket, RI.

Leave a Reply

Your email address will not be published. Required fields are marked *